What AKCEA THERAPEUTICS, INC.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Jenne Kyle | Chief Commercial Officer | Oct 12 | Tender Offer · U | −52,012 | $18.15 | −$944K | 0 |
| Andrews William T. | Chief Medical Officer | Oct 12 | Tender Offer · U | −37,500 | $18.15 | −$681K | 0 |
| Patterson Joshua F. | General Counsel | Oct 12 | Tender Offer · U | −26,532 | $18.15 | −$482K | 0 |
| Price Michael Dennis | Chief Financial Officer | Oct 12 | Tender Offer · U | −50,000 | $18.15 | −$908K | 0 |
| McDevitt Damien | Chief Executive Officer | Oct 12 | Tender Offer · U | −242,978 | $18.15 | −$4.41M | 0 |
| Howarth Alex G. | Chief Operating Officer | Oct 12 | Tender Offer · U | −66,800 | $18.15 | −$1.21M | 0 |
| Isis Pharmaceuticals Inc | 10% owner | Oct 10 | Open-market buy · P | +21,237,715 | $18.15 | +$385M | 98,322,397 |
| Jenne Kyle | Chief Commercial Officer | Sep 22 | Open-market sale · S | −720 | $18.12 | −$13K | 52,012 |
| Patterson Joshua F. | General Counsel | Sep 22 | Open-market sale · S | −319 | $18.12 | −$5.78K | 26,532 |
| McDevitt Damien | Chief Executive Officer | Sep 22 | Open-market sale · S | −8,709 | $18.12 | −$158K | 242,978 |
| McDevitt Damien | Chief Executive Officer | Aug 31 | Grant / award · A | +1,104 | $14.40 | +$15.9K | 251,687 |
| Patterson Joshua F. | General Counsel | Jul 17 | Open-market sale · S | −263 | $12.50 | −$3.29K | 26,851 |
| Andrews William T. | Chief Medical Officer | Jul 09 | Grant / award · A | +37,500 | — | — | 37,500 |
| Price Michael Dennis | Chief Financial Officer | May 18 | Grant / award · A | +50,000 | — | — | 50,000 |
| Patterson Joshua F. | General Counsel | Apr 15 | Grant / award · A | +12,500 | — | — | 27,114 |
| Jenne Kyle | Chief Commercial Officer | Mar 23 | Open-market sale · S | −779 | $11.75 | −$9.15K | 52,732 |
| Patterson Joshua F. | General Counsel | Mar 23 | Open-market sale · S | −335 | $11.76 | −$3.94K | 14,614 |
| McDevitt Damien | Chief Executive Officer | Mar 23 | Open-market sale · S | −9,417 | $11.75 | −$111K | 245,783 |
| O'Dea Louis | Chief Medical Officer | Mar 23 | Open-market sale · S | −3,198 | $11.75 | −$37.6K | 61,602 |
| Jenne Kyle | Chief Commercial Officer | Mar 19 | Grant / award · A | +16,800 | — | — | 53,511 |
Loading...
